Traws Pharma Inc (NASDAQ:TRAW) — Market Cap & Net Worth
Market Cap & Net Worth: Traws Pharma Inc (TRAW)
Traws Pharma Inc (NASDAQ:TRAW) has a market capitalization of $11.91 Million ($11.91 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26434 globally and #5276 in its home market, demonstrating a 22.13% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Traws Pharma Inc's stock price $1.49 by its total outstanding shares 7990867 (7.99 Million). Analyse Traws Pharma Inc cash conversion from operations to see how efficiently the company converts income to cash.
Traws Pharma Inc Market Cap History: 2015 to 2026
Traws Pharma Inc's market capitalization history from 2015 to 2026. Data shows change from $430.07 Billion to $11.91 Million (-64.51% CAGR).
Index Memberships
Traws Pharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #758 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2496 of 3165 |
Weight: Traws Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Traws Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Traws Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
328.47x
Traws Pharma Inc's market cap is 328.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $430.07 Billion | $11.46 Million | -$23.98 Million | 37540.89x | N/A |
| 2016 | $102.03 Billion | $5.55 Million | -$19.67 Million | 18397.65x | N/A |
| 2017 | $67.42 Billion | $787.00K | -$24.09 Million | 85670.83x | N/A |
| 2018 | $6.32 Billion | $1.23 Million | -$20.57 Million | 5148.84x | N/A |
| 2019 | $1.15 Billion | $2.18 Million | -$21.50 Million | 525.74x | N/A |
| 2020 | $1.40 Billion | $231.00K | -$25.16 Million | 6042.44x | N/A |
| 2021 | $509.42 Million | $226.00K | -$16.16 Million | 2254.06x | N/A |
| 2022 | $128.99 Million | $226.00K | -$18.96 Million | 570.76x | N/A |
| 2023 | $148.95 Million | $226.00K | -$18.95 Million | 659.07x | N/A |
| 2024 | $74.24 Million | $226.00K | -$54.67 Million | 328.47x | N/A |
Competitor Companies of TRAW by Market Capitalization
Companies near Traws Pharma Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Traws Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Traws Pharma Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Traws Pharma Inc's market cap moved from $430.07 Billion to $ 11.91 Million, with a yearly change of -64.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.91 Million | +31.86% |
| 2025 | $9.03 Million | -87.84% |
| 2024 | $74.24 Million | -50.16% |
| 2023 | $148.95 Million | +15.47% |
| 2022 | $128.99 Million | -74.68% |
| 2021 | $509.42 Million | -63.50% |
| 2020 | $1.40 Billion | +21.62% |
| 2019 | $1.15 Billion | -81.85% |
| 2018 | $6.32 Billion | -90.62% |
| 2017 | $67.42 Billion | -33.92% |
| 2016 | $102.03 Billion | -76.28% |
| 2015 | $430.07 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Traws Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.91 Million USD |
| MoneyControl | $11.91 Million USD |
| MarketWatch | $11.91 Million USD |
| marketcap.company | $11.91 Million USD |
| Reuters | $11.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marbox… Read more